Literature DB >> 3746533

Pulmonary function abnormalities in homozygous beta-thalassemia.

R W Hoyt, N Scarpa, R W Wilmott, A Cohen, E Schwartz.   

Abstract

Pulmonary function tests were performed on 19 patients with homozygous beta-thalassemia ranging in age from 10 to 29 years. These included patients who had and had not received transfusions. None of the 19 subjects had completely normal pulmonary function. Residual volume (in 16 of 19 patients), ratio of residual volume to total lung capacity (12 of 19), and airway resistance (16 of 19) were abnormally increased; maximum expiratory flow (15 of 19) and peak flow (10 of 19) were abnormally reduced. Single-breath carbon monoxide diffusion was normal in 16 of 19. These results indicate that mild to moderate small airway obstruction and hyperinflation are common in thalassemia and that patient age, transfusion history, and iron accumulation are not important factors in the genesis of these pulmonary abnormalities.

Entities:  

Mesh:

Year:  1986        PMID: 3746533     DOI: 10.1016/s0022-3476(86)80116-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  Pulmonary function tests in beta thalassemia.

Authors:  M Arora; J Chandra; J C Suri; S Narayan; A K Dutta
Journal:  Indian J Pediatr       Date:  2001-03       Impact factor: 1.967

2.  Pulmonary function in thalassaemia major and its correlation with body iron stores.

Authors:  Eugene Y Sohn; Leila J Noetzli; Aakanksha Gera; Roberta Kato; Thomas D Coates; Paul Harmatz; Thomas G Keens; John C Wood
Journal:  Br J Haematol       Date:  2011-08-02       Impact factor: 6.998

Review 3.  Sleep Disturbances in Neurodevelopmental Disorders.

Authors:  Althea Robinson-Shelton; Beth A Malow
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

Review 4.  How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders.

Authors:  Evans M Machogu; Roberto F Machado
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.